Financial Performance - Revenue for the year ended December 31, 2025, was RMB 1,292.9 million, a decrease of 4.1% compared to RMB 1,348.4 million for the year ended December 31, 2024[3] - Net profit for the year ended December 31, 2025, was RMB 24.1 million, down 33.8% from RMB 36.5 million for the year ended December 31, 2024[5] - Operating profit for the year ended December 31, 2025, was RMB 22.5 million, compared to RMB 27.8 million for the year ended December 31, 2024[7] - The company reported a total comprehensive income of RMB 15.3 million for the year ended December 31, 2025, down from RMB 29.4 million for the year ended December 31, 2024[8] - Basic and diluted earnings per share for the year ended December 31, 2025, were RMB 0.15, compared to RMB 0.23 for the year ended December 31, 2024[8] Assets and Liabilities - Total assets as of December 31, 2025, amounted to RMB 1,055.4 million, down from RMB 1,189.9 million as of December 31, 2024[9] - Current assets as of December 31, 2025, were RMB 947.7 million, compared to RMB 1,086.6 million as of December 31, 2024[9] - Total liabilities for 2025 amount to RMB 396,303,000, while for 2024, it was RMB 469,480,000, indicating a decrease of approximately 15.6%[11] - Current liabilities for 2025 are RMB 382,685,000, compared to RMB 440,902,000 in 2024, reflecting a reduction of about 13.2%[11] - Non-current liabilities total RMB 13,618,000 for 2025, down from RMB 28,578,000 in 2024, showing a decline of approximately 52.4%[11] Revenue Breakdown - B2B sales contributed RMB 656,100 thousand in 2025, up from RMB 649,007 thousand in 2024, while B2C sales decreased to RMB 633,150 thousand from RMB 687,817 thousand[22] - Health products revenue grew significantly by 67.2% year-on-year, reaching RMB 241.8 million, accounting for 18.7% of total revenue[57] - The revenue from adult personal care products decreased by 14.0% to RMB 764.7 million, primarily due to the termination of a strategic partnership with a personal care brand[57] - Revenue from cross-border e-commerce increased by 41.0% to RMB 240.2 million, reflecting a growing market segment[59] Dividends - The board proposed a final dividend of HKD 0.25 per share for the year ended December 31, 2025[6] - The proposed final dividend for the year ended December 31, 2025, is HKD 0.25 per share, totaling HKD 41.5 million (approximately RMB 36.5 million), down from HKD 82.9 million (approximately RMB 75.9 million) in 2024[51] - The company will not declare an interim dividend for the six months ended June 30, 2025, compared to an interim dividend of HKD 0.25 per share for the same period in 2024[50] Corporate Governance - The board of directors consists of three executive directors, one non-executive director, and three independent non-executive directors, ensuring a balanced governance structure[95] - The audit committee, comprising three independent non-executive directors, is responsible for reviewing the company's financial reporting system and internal controls[100] - The company has adopted the corporate governance code and is committed to maintaining high standards of corporate governance[93] Strategic Focus - The company plans to strategically invest in the health sector, focusing on acquiring external quality brands and enhancing its own brand matrix[90] - The company aims to optimize existing core businesses, innovate products and services, and strengthen digital capabilities to drive high-quality growth[90] - The company is actively optimizing its brand matrix and focusing on high-growth potential business areas to mitigate low-price competition risks[54] Cash Flow and Financing - The net cash used in operating activities was RMB 93.8 million, a significant decline from the previous year, primarily due to increased inventory costs related to brand expansion and extended reimbursement periods for promotional expenses[71] - The net cash generated from investing activities was RMB 14.8 million, mainly from receiving dividends of RMB 15.6 million from joint ventures[71] - The net cash used in financing activities was RMB 53.7 million, primarily due to dividend payments of RMB 75.6 million to shareholders, offset by cash obtained from new borrowings of RMB 21.9 million[72] Market Environment - The macro environment shows a moderate recovery in consumer markets, which the company plans to leverage for sustainable development in 2026[88]
优趣汇控股(02177) - 2025 - 年度业绩